Novartis signs USD 7.8 billion deal. Novartis stock gains 1.87 percent.

Novartis has signed a messenger RNA licensing deal worth up to USD 7.8 billion with Abogen Biosciences, CNBC reported on October 2, 2026. Novartis stock was trading at EUR 126.94 at Lang & Schwarz on October 7, 2026 at 10:18 a.m. CEST, plus 1.87 percent versus the prior close of EUR 124.61.

RNA deal adds pipeline optionality

The agreement gives Novartis exclusive worldwide rights to ABO2203, an experimental messenger RNA treatment aimed at autoimmune disease, plus options on additional programs from Abogen's RNA platform, according to CNBC.

Novartis will pay USD 575 million upfront, while as much as USD 7.2 billion is tied to research, regulatory and commercial milestones. The structure limits the initial cash commitment relative to the headline value, but much of the potential consideration depends on clinical and commercial progress.

Second-quarter revenue sets the baseline

For the second quarter of 2026, Novartis reported revenue of CHF 14.16 billion and net profit of CHF 3.21 billion, compared with CHF 14.84 billion and CHF 4.04 billion, respectively, a year earlier, according to Markets Insider.

The comparison matters because the new RNA investment arrives while Novartis is replenishing its development pipeline. The company's investor page identifies October 27, 2026 as the date for its third-quarter financial results, providing the next scheduled test of sales and profit momentum, Novartis states.

Analyst caution contrasts with deal size

Berenberg analyst Kerry Holford maintained a Hold rating and set a CHF 105.00 price target on October 6, 2026, according to Markets Insider. The target is below the quoted CHF 116.48 closing level cited in that report, showing that the large pipeline transaction has not removed near-term valuation caution.

Novartis trades on the SIX Swiss Exchange under ticker NOVN. Its reported 52-week range was CHF 97.05 to CHF 132.68 on October 6, 2026, keeping the Swiss listing below its recorded high while the euro quote remains distinct from the CHF reference.

Next results set the next marker

The October 27, 2026 third-quarter report will give investors a fresher read on operating performance than the October 2 deal announcement. Until then, the key balance is between the USD 575 million upfront payment, the USD 7.2 billion milestone pool and the CHF 14.16 billion second-quarter revenue base. The further course of trading is shown by the continuously updated real-time quote of Novartis stock.

More news and analyses on Novartis stock